3.2. Joint Pain K-VAS
pain
SECONDARY
Mean joint pain K-VAS values were similar for the FP-MD and placebo groups at baseline (For the secondary efficacy endpoint (the difference between groups from baseline to week 6 in the change in joint pain K-VAS scores), there was no statistically significant difference between groups (